Table 1 Characteristics of the included studies
# | Author/Study | Country | Study Design | Study Populationa | Age range (yrs) (Mean, range/SD) | Analyzer | Flow rate (L/min) | Measurement Methodb | Cut – off (nL/min) | Inclusion criteria/ Diagnosis |
|---|---|---|---|---|---|---|---|---|---|---|
1 | Narang I (2002) [26] | United Kingdom | Case - Control | 31 PCD 53 HC | PCD: 11.0 (5.5–17.3) HC: 10.7 (5.5–19.0) | LR 2000 | 0.25 | BH | 62.5 | HSVM and TEM |
2 | Corbelli R (2004) [23] | Switzerland | Prospective Cohort | 17 PCD 17 non PCD (BE,B) | All: 11.4 (1.2) | CLD88sp | 1.20 | BH | 126 | TEM |
3 | Piacentini G (2008) [25] | Italy | Case - Control | 10 PCD 27 HC | PCD: 17 (−) HC: 7 (−) | NIOX Flex | 0.30 | BH | 21.3 | TEM |
4 | Mateos Coral D (2011) [31] | Canada | Case – Control (with longitudinal follow-up in a subsample) | 20 PCD 65 non PCD (CF,BE,HC) | PCD: 11.4 (3.5) HC: 11.0 (3.7) CF: 11.0 (3.4) BE: 10.9(3.3) | CLD88sp | 0.33 | ER & TB | ER: 58.5 TB: 37.1 | TEM |
5 | Marthin JK (2011) [22] Substudy 3 | Denmark | Prospective Cohort | 20 PCD 97 non PCD | All: 6.9 (0.0–62.4)c | NIOX Flex | 0.30 | BH & TB | BH: 52.5 TB: 47.4 | HSVM and TEM |
6 | Marthin JK (2011) [22] Substudy 2 | Denmark | Case - Control | 59 PCD 57 HC | PCD: 17.4 (3.6–65.8)c Non PCD:29.5 (3.1–63.6)c | NIOX Flex | 0.30 | BH & TB | BH: 52.5 TB: 47.4 | HSVM and/or TEM |
7 | Leigh M (2013) [7] | United States | Prospective Cohort | 71 PCD 84 non-PCD | PCD: 23.3(18) Non PCD: 31.8 (22.3) | Sievers 280i CLD88sp NIOX Flex | 0.50 0.33 0.30 | ER | 76.9 | TEM and DNA |
8 | Boon M (2014) [30] | Belgium | Case - Control | 38 PCD 188 non PCD (HC, CF, Asthma, HID) | PCD: 14.3 (8.8–18.1)c HC: 14.9 (10.8–20.4)c CF: 14.0 (9.2–17.9)c Asthma: 12.1 (9.8–16.5)c HID: 10.7 (8.2–15.6)c | CLD88sp | 0.30 | ER & TB | ER: 90 TB: 60 | HSVM and TEM (and culture) |
9 | Harris A (2014) [14] | United Kingdom | Case - Control | 13 PCD 37 non PCD (HC,CF, CSLD) | PCD: 23 (5–71) HC: 31 (8–65) CF: 15(6–29) CSLD: 36 (8–79) | NIOX Flex NIOX MINO | 0.30 | BH & TB | BH: 38 TB: 30 | HSVM and TEM (and culture for some) |
10 | Montella S (2012) [27] | Italy | Case - Control | 23 PCD 23 HC | PCD: 15.8 (4.6–32.8)c HC: 15.7 (4.3–32.1)c | NIOX MINO | 0.30 | TB | 17.4 | HSVM and TEM |
11 | Santamaria F (2008) [28] | Italy | Case - Control | 14 PCD 14 HC | PCD: 15 (7–27) HC:16 (7–27) | NIOX Flex | 0.28 | BH | 7.2 | TEM |
12 | Moreno Caldo A (2010) [29] | Spain | Case Control | 9 PCD 112 non PCD (HC, CF, Asthma,BE) | PCD: − (7–14) HC: − (−) CF: − (6–14) Asthma: (6–17) BE: − (6–14) | LR2000 | 0.25 | BH | 28 | TEM |
13 | Beydon M 2015 [24] | France | Prospective Cohort | 49 PCD 37 non-PCD | PCD: 11.4 (7,13.9)d Non PCD: 7.9 (4.9,11.6)d | NIOX Flex Endono 8000 | 0.30 | BH/ER TB | BH/ER: 82.2 TB: 39.9 | HSVM, TEM and/or DNA |